title: [Targeted agents in the treatment of lung cancer].
abstract: Lung cancer is in France, the leading cause of cancer death. Despite the dramatic advances that have allowed in a few years to go, for metastatic cancer, from a median survival without specific treatment of 4.5 months and now almost always more than one year, survival remains disappointing and further improvements are needed. Progress in the accumulated knowledge of the inner workings of normal and tumoral cells have paved the way for the development of targeted therapeutics called biological or simply targeted therapies. Two biological processes are already the target of marketed drugs, this is the way the receptor of epidermal growth factor (EGFR) and the path of neo-angiogenesis. It is almost assumed that, in the very near future, the inhibition of EML4-ALK will also be the subject of new drugs. In the medium term, it is conceivable that the molecular dissection of the tumors actually lead to the prescription of treatments tailored to mutations and other abnormalities that direct the growth of cancers.
authors: Service de pneumologie, hôpital Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France.
authors: L
authors: L
authors: Staudacher
authors: L
authors: L
authors: Teixeira
authors: E
authors: E
authors: Kempf
authors: G
authors: G
authors: Rousseau-Bussac
authors: S
authors: S
authors: Jouveshomme
authors: R
authors: R
authors: Cohen
authors: C
authors: C
authors: Beuzelin
authors: J-L
authors: JL
authors: Jagot
authors: S
authors: S
authors: Salmeron
authors: J
authors: J
authors: Trédaniel
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000187:drug effects / Q000235:genetics; D005260:Female; D005602:France; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic
chemical_list: D020533:Angiogenesis Inhibitors; D066246:ErbB Receptors